NASDAQ:TMDX TransMedics Group (TMDX) Stock Price, News & Analysis → The AI Defense Stock Set to Soar (From Behind the Markets) (Ad) Free TMDX Stock Alerts $74.12 -0.37 (-0.50%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$73.88▼$77.2250-Day Range$70.86▼$89.9352-Week Range$36.42▼$99.63Volume594,119 shsAverage Volume739,764 shsMarket Capitalization$2.42 billionP/E RatioN/ADividend YieldN/APrice Target$103.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get TransMedics Group alerts: Email Address TransMedics Group MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside40.0% Upside$103.75 Price TargetShort InterestBearish16.54% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.24Based on 6 Articles This WeekInsider TradingSelling Shares$7.71 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.22) to $0.22 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.41 out of 5 starsMedical Sector528th out of 939 stocksElectromedical Equipment Industry4th out of 18 stocks 3.4 Analyst's Opinion Consensus RatingTransMedics Group has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $103.75, TransMedics Group has a forecasted upside of 40.0% from its current price of $74.12.Amount of Analyst CoverageTransMedics Group has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted16.54% of the outstanding shares of TransMedics Group have been sold short.Short Interest Ratio / Days to CoverTransMedics Group has a short interest ratio ("days to cover") of 9.Change versus previous monthShort interest in TransMedics Group has recently increased by 8.63%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTransMedics Group does not currently pay a dividend.Dividend GrowthTransMedics Group does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TMDX. Previous Next 4.0 News and Social Media Coverage News SentimentTransMedics Group has a news sentiment score of 1.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for TransMedics Group this week, compared to 4 articles on an average week.Search Interest22 people have searched for TMDX on MarketBeat in the last 30 days. This is an increase of 83% compared to the previous 30 days.MarketBeat Follows15 people have added TransMedics Group to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TransMedics Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,710,719.00 in company stock.Percentage Held by InsidersOnly 6.70% of the stock of TransMedics Group is held by insiders.Percentage Held by Institutions99.67% of the stock of TransMedics Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for TransMedics Group are expected to grow in the coming year, from ($0.22) to $0.22 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TransMedics Group is -96.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TransMedics Group is -96.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTransMedics Group has a P/B Ratio of 17.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the Markets4x Better than Bitcoin4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About TransMedics Group Stock (NASDAQ:TMDX)TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.Read More TMDX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TMDX Stock News HeadlinesMarch 13, 2024 | insidertrades.comInsider Selling: TransMedics Group, Inc. (NASDAQ:TMDX) Insider Sells 1,417 Shares of StockMarch 13, 2024 | insidertrades.comStephen Gordon Sells 1,903 Shares of TransMedics Group, Inc. (NASDAQ:TMDX) StockMarch 28, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 25, 2024 | markets.businessinsider.comTransMedics Group: Operational Efficiency and Market Positioning Propel Buy RatingMarch 24, 2024 | americanbankingnews.comTransMedics Group (NASDAQ:TMDX) Stock Price Down 4.3%March 24, 2024 | americanbankingnews.comTransMedics Group, Inc. (NASDAQ:TMDX) Receives Average Rating of "Moderate Buy" from BrokeragesMarch 22, 2024 | seekingalpha.comTransMedics: Strong Business, Fully Valued StockMarch 19, 2024 | finance.yahoo.comTMDX Jul 2024 135.000 callMarch 28, 2024 | Behind the Markets (Ad)The Small Biotech with a BIG Cancer SolutionThere's a new cancer treatment so precise, it's been called a "smart bomb." One that can deliver a toxic payload directly to tumors while bypassing healthy cells.March 12, 2024 | seekingalpha.comTransMedics Group: Huge Opportunity In Organ TransplantsMarch 5, 2024 | finance.yahoo.comJim Cramer’s Latest Lightning Round: 11 Stock RecommendationsMarch 3, 2024 | markets.businessinsider.comROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages TransMedics Group, Inc. Investors to Inquire About Securities Class Action Investigation - TMDXMarch 3, 2024 | finance.yahoo.comBrokers Are Upgrading Their Views On TransMedics Group, Inc. (NASDAQ:TMDX) With These New ForecastsMarch 3, 2024 | fool.com2 No-Brainer Growth Stocks to Buy With $100 in MarchMarch 2, 2024 | prnewswire.comTMDX INVESTOR NOTICE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages TransMedics Group, Inc. Investors to Inquire About Securities Class Action Investigation - TMDXMarch 1, 2024 | fool.com3 Healthcare Stocks That Have Outperformed Nvidia Since 2022February 29, 2024 | finance.yahoo.comTransMedics Group, Inc. (NASDAQ:TMDX) Just Reported Full-Year Earnings And Analysts Are Lifting Their EstimatesFebruary 28, 2024 | markets.businessinsider.comCracking The Code: Understanding Analyst Reviews For TransMedics GrFebruary 28, 2024 | prnewswire.comTransMedics to Present at Upcoming March Investor ConferencesFebruary 28, 2024 | finanznachrichten.deTransMedics Group, Inc.: TransMedics Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 28, 2024 | nasdaq.comTransMedics Group Becomes Oversold (TMDX)February 28, 2024 | seekingalpha.comTransMedics Group, Inc. (TMDX) Q4 2023 Earnings Call TranscriptFebruary 27, 2024 | msn.comOrgan Transplant-Focused TransMedics Clocks Q4 Profit On Increased Use Of Its Organ Care System, Analysts Optimistic About Integrated Aviation BusinessFebruary 27, 2024 | finance.yahoo.comQ4 2023 Transmedics Group Inc Earnings CallFebruary 27, 2024 | tmcnet.comROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages TransMedics Group, Inc. Investors to Inquire About Securities Class Action Investigation - TMDXFebruary 26, 2024 | marketwatch.comTransMedics Shares Rise 19% as Company Reports 4Q GainFebruary 26, 2024 | msn.comTransMedics Group GAAP EPS of $0.12 beats by $0.16, revenue of $81.2M beats by $12.7MSee More Headlines Receive TMDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TransMedics Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/26/2024Today3/28/2024Next Earnings (Estimated)5/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical equipment Sub-IndustryN/A Current SymbolNASDAQ:TMDX CUSIPN/A CIK1756262 Webwww.transmedics.com Phone(978) 552-0900FaxN/AEmployees584Year FoundedN/APrice Target and Rating Average Stock Price Target$103.75 High Stock Price Target$110.00 Low Stock Price Target$95.00 Potential Upside/Downside+40.0%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-25,030,000.00 Net Margins-10.36% Pretax Margin-11.04% Return on Equity-2.35% Return on Assets-0.60% Debt Debt-to-Equity Ratio3.69 Current Ratio9.30 Quick Ratio8.49 Sales & Book Value Annual Sales$241.62 million Price / Sales10.03 Cash Flow$0.14 per share Price / Cash Flow523.33 Book Value$4.20 per share Price / Book17.65Miscellaneous Outstanding Shares32,700,000Free Float30,509,000Market Cap$2.42 billion OptionableOptionable Beta2.01 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Waleed H. Hassanein M.D. (Age 56)Founder, President, CEO & Director Comp: $1.46MMr. Stephen Gordon (Age 56)CFO, Treasurer & Secretary Comp: $744.62kDr. Tamer I. Khayal M.D. (Age 55)Chief Commercial Officer Comp: $748.78kMs. Miriam C. Provost Ph.D. (Age 63)Vice President of Global Regulatory Affairs Comp: $535.93kMr. Nick Corcoran (Age 42)Senior Vice President of Supply Chain & Operations Mr. Mark AndersonSenior Director of Technology DevelopmentMr. Anil RanganathSenior VP, General Counsel & Corporate SecretaryMs. Susan GoodmanVice President of Human ResourcesMore ExecutivesKey CompetitorsCONMEDNYSE:CNMDLivaNovaNASDAQ:LIVNInModeNASDAQ:INMDIntegerNYSE:ITGRBioLife SolutionsNASDAQ:BLFSView All CompetitorsInsiders & InstitutionsHighPoint Advisor Group LLCBought 7,640 shares on 3/26/2024Ownership: 0.023%Vanguard Group Inc.Bought 50,673 shares on 3/11/2024Ownership: 5.700%Tamer I KhayalSold 1,417 sharesTotal: $124,412.60 ($87.80/share)Stephen GordonSold 1,903 sharesTotal: $166,759.89 ($87.63/share)Stephen GordonSold 15,000 sharesTotal: $1.24 M ($82.80/share)View All Insider TransactionsView All Institutional Transactions TMDX Stock Analysis - Frequently Asked Questions Should I buy or sell TransMedics Group stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TransMedics Group in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TMDX shares. View TMDX analyst ratings or view top-rated stocks. What is TransMedics Group's stock price target for 2024? 6 analysts have issued twelve-month price objectives for TransMedics Group's stock. Their TMDX share price targets range from $95.00 to $110.00. On average, they predict the company's stock price to reach $103.75 in the next year. This suggests a possible upside of 40.0% from the stock's current price. View analysts price targets for TMDX or view top-rated stocks among Wall Street analysts. How have TMDX shares performed in 2024? TransMedics Group's stock was trading at $78.93 at the beginning of 2024. Since then, TMDX stock has decreased by 6.1% and is now trading at $74.12. View the best growth stocks for 2024 here. When is TransMedics Group's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024. View our TMDX earnings forecast. How were TransMedics Group's earnings last quarter? TransMedics Group, Inc. (NASDAQ:TMDX) released its quarterly earnings data on Monday, February, 26th. The company reported $0.12 EPS for the quarter, topping analysts' consensus estimates of ($0.10) by $0.22. The business had revenue of $81.20 million for the quarter, compared to analysts' expectations of $68.49 million. TransMedics Group had a negative net margin of 10.36% and a negative trailing twelve-month return on equity of 2.35%. The firm's revenue for the quarter was up 158.6% compared to the same quarter last year. During the same period last year, the business earned ($0.21) EPS. What ETFs hold TransMedics Group's stock? ETFs with the largest weight of TransMedics Group (NASDAQ:TMDX) stock in their portfolio include Clough Select Equity ETF (CBSE), Clough Long/Short Equity ETF (CBLS), Innovator IBD 50 ETF (FFTY), Alger 35 ETF (ATFV), SPDR S&P Health Care Equipment ETF (XHE), BNY Mellon Innovators ETF (BKIV), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) and First Trust Multi-Manager Small Cap Opportunities ETF (MMSC). What guidance has TransMedics Group issued on next quarter's earnings? TransMedics Group updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $360.0 million-$370.0 million, compared to the consensus revenue estimate of $330.2 million. What is Waleed Hassanein's approval rating as TransMedics Group's CEO? 17 employees have rated TransMedics Group Chief Executive Officer Waleed Hassanein on Glassdoor.com. Waleed Hassanein has an approval rating of 83% among the company's employees. What other stocks do shareholders of TransMedics Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other TransMedics Group investors own include Advanced Micro Devices (AMD), Roku (ROKU), AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), RTX (RTX), Yamana Gold (AUY), B2Gold (BTG), Beyond Meat (BYND) and Walt Disney (DIS). When did TransMedics Group IPO? TransMedics Group (TMDX) raised $75 million in an initial public offering (IPO) on Thursday, May 2nd 2019. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers. Who are TransMedics Group's major shareholders? TransMedics Group's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (5.71%), Vanguard Group Inc. (5.70%), Eventide Asset Management LLC (3.05%), Sandhill Capital Partners LLC (2.34%), First Light Asset Management LLC (2.31%) and Allspring Global Investments Holdings LLC (2.17%). Insiders that own company stock include David Weill, Edward M Basile, Edwin M Kania Jr, James R Tobin, John F Carey, John F Sullivan, Laura Damme, Miriam Provost, Stephanie Lovell, Stephen Gordon, Tamer I Khayal, Tamer I Khayal and Waleed H Hassanein. View institutional ownership trends. How do I buy shares of TransMedics Group? Shares of TMDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TMDX) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransMedics Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.